Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation (2013 - 2016)

Viridian Therapeutics, Inc.\DE's Accumulated Depreciation history runs 4 years deep, the most recent figure standing at $881000.0 for Q3 2016.

• In Q3 2016, Accumulated Depreciation rose 27.31% year-over-year to $881000.0; the TTM figure through Sep 2016 stood at $881000.0 (up 27.31% YoY), while the FY2015 annual figure was $739000.0, up 33.15% from the prior year.
• Accumulated Depreciation for Q3 2016 stood at $881000.0, up from $834000.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $881000.0 in Q3 2016, with the low at $411000.0 in Q4 2013.
• The 4-year median for Accumulated Depreciation is $645000.0 (2015), against an average of $649437.1.
• The sharpest annual moves came in 2014 and 2016: Accumulated Depreciation surged 35.04% in 2014, then rose 27.31% in 2016.
• Viridian Therapeutics, Inc.\DE's Accumulated Depreciation stood at $411000.0 in 2013, then soared by 35.04% to $555000.0 in 2014, then jumped by 33.15% to $739000.0 in 2015, then advanced by 19.22% to $881000.0 in 2016.
• Business Quant data shows VRDN's Accumulated Depreciation at $881000.0 in Q3 2016, $834000.0 in Q2 2016, and $786000.0 in Q1 2016.